From: Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C
Assessment | Treatment start | Frequency |
---|---|---|
General | ||
· Complete physical examination | ✔ | Every 3–6 months |
Clinical parameters of neurological disease | ||
· NP-C functional disability scale | ✔ | Every 6–12 months |
· Video recording | ✔ | Every 6–12 months |
· Epileptic seizures | ✔ | Every 6–12 months |
· Narcolepsy/cataplexy | ✔ | Every 6–12 months |
Other measures | ||
· Psychometric evaluations | ✔ | Every 6–12 months |
· Hearing | ✔ | Every 6–12 months |
· Abdominal ultrasound | ✔ | Depending on initial findings |
· Chest X-ray | ✔ | Initial assessment and depending on clinical evolution |
Laboratory parameters | ||
· Liver function | ✔ | Every 6–12 months |
· Haematology (blood counts) | ✔ | Every 6–12 months |
· Plasma chitotriosidase (optional) | ✔ | Initial assessment |
Cerebral imaging | ||
· MRI or MRS (magnetic resonance spectroscopy)* | ✔ | Every 12 months |